摘要
目的探讨与分析乳腺1号方口服联合外敷治疗肝郁气滞型乳腺增生的有效性及安全性。方法选取2021年5月—2022年5月在北京市密云区中医医院诊治的肝郁气滞型乳腺增生患者70例作为研究对象,根据随机数表法把患者分为联合组与对照组,各35例。对照组给予乳腺1号方口服治疗,联合组给予乳腺1号方口服联合外敷治疗,两组都治疗观察4周,记录治疗的有效性与安全性情况,判定乳房肿块与乳房疼痛评分变化情况,测量乳房直径变化情况,检测血清催乳素与雌二醇含量变化情况。结果所有患者都完成治疗,治疗期间无严重不良反应。治疗后联合组的总有效率高于对照组,但差异无统计学意义(P>0.05)。两组治疗后的乳房肿块硬度评分与乳房疼痛评分、乳房肿块直径都明显低于治疗前(P<0.05),治疗后联合组各项评分及乳房肿块直径明显低于对照组(P<0.05)。两组治疗后的血清催乳素与雌二醇含量都明显低于治疗前(P<0.05),治疗后联合组也明显低于对照组(P<0.05)。结论乳腺1号方口服联合外敷治疗肝郁气滞型乳腺增生能抑制催乳素与雌二醇的释放,促进缩小乳房肿块直径,缓解患者的乳房肿块硬度与乳房疼痛症状,提高总体治疗效果。
Objective To investigate and analysis the efficacy and safety of oral Breast No.1 combined with external application in the treatment of hyperplasia of mammary glands with liver depression and qi stagnation.Methods From May 2021 to May 2022,70 cases of patients with mammary gland hyperplasia of liver depression and qi stagnation type diagnosed and treated in Beijing Miyun District Hospital of Traditional Chinese Medicine were selected as the research objects.The patients were randomly divided into the combined group and the control group with 35 cases each accorded to the numerical table.The control group were treated with oral Chinese medicine,and the combined group were treated with oral Breast No.1 combined with external application.Both groups were treated and observed for 4 weeks,and recorded the effectiveness and safety of treatment,determined the changes of breast lump and breast pain score,measure the changes of breast diameter,and detected the changes of serum prolactin and estradiol.Results All patients were completed the treatment,and there were no serious adverse reactions occurred during the treatment.The total response rates in the post-treatment combination group was higher than the control group,and it was not significant between the groups(P>0.05).The scores of breast lump and breast pain,diameter of breast masses in the two groups after treatment were significantly lower than those before treatment(P<0.05),and the scores of breast lump hardness and breast pain,diameter of breast masses in the combined group after treatment were significantly lower than those in the control group(P<0.05).The levels of serum prolactin and estradiol in the two groups after treatment were significantly lower than those before treatment(P<0.05),and the combined group after treatment were also significantly lower than those in the control group(P<0.05).Conclusion Oral Breast No.1 combined with external application can inhibit the release of prolactin and estradiol,promote the reduction of breast mass diameter,alleviat
作者
王雅芹
WANG Ya-qin(Surgery department of Beijing Miyun District Hospital of Traditional Chinese Medicine,Beijing 101500,China)
出处
《中华养生保健》
2023年第12期27-30,共4页
CHINESE HEALTH CARE
关键词
乳腺1号方
中药外敷
肝郁气滞型
乳腺增生
催乳素
乳房肿块直径
乳房疼痛
oral breast No.1
external application of traditional chinese medicine
liver qi stagnation type
hyperplasia of mammary glands
Prolactin
diameter of breast lump
breast pain
